Pause to US trial of Oxford vaccine could threaten its success

Disruption to a US trial of the Oxford vaccine against the coronavirus disease (COVID-19) means it could miss a vital deadline to give its participants a secondary dose, it has been revealed. (Reuters/File Photo)
Short Url
Updated 07 October 2020
Follow

Pause to US trial of Oxford vaccine could threaten its success

  • The Oxford team in charge of the trial is at the forefront of the race to develop a working vaccine
  • Trial volunteers should receive a second dose 28 days after their first, with regulations only allowing for a three-day grace period

LONDON: Disruption to a US trial of the Oxford vaccine against the coronavirus disease (COVID-19) means it could miss a vital deadline to give its participants a secondary dose, it was revealed on Wednesday.

Due to a month-long halt of the trial imposed by US regulators investigating potential side-effects, volunteers have only been given one dose of the vaccine and are in danger of missing out on the necessary booster shot, the Times newspaper reported.

The Oxford team in charge of the trial is at the forefront of the race to develop a working vaccine, but could now face challenges in determining its effectiveness due to the pause in the US.

Enrollment in other trials in several countries around the world, being run by AstraZeneca in conjunction with researchers at Oxford University, was put on hold in September, after a participant in its UK trial suffered a rare spinal inflammatory disorder known as transverse myelitis.

While the British trial continued soon afterward — along with other testing in South Africa, Brazil, Japan and India — the American trial remains postponed.

“There is quite a lot of evidence that a longer interval (between shots) is actually better ... However, changing the interval midway through a trial can be problematic. Anyone who doesn’t get their vaccinations according to the stated schedule should be excluded from the final analysis of the trial,” Eleanor Riley, professor of immunology at the University of Edinburgh, told the Times.

“That means they may have to recruit additional people to make up the numbers. That will obviously add more delay to getting an answer.

“If a large group is affected by the delay, they may analyze their data anyway, as a secondary subgroup analysis, to see if the difference in timing has any effect,” she added.

Trial volunteers should receive a second dose 28 days after their first, with regulations only allowing for a three-day grace period.

AstraZeneca declined to confirm how many participants had been injected in the US before the trial was paused when asked by the Times.

However, AstraZeneca executive Mene Pangalos said the US trial was more of a confirmatory trial, according to a client note from Guggenheim.

The note also said that the US pause would not have much bearing on the vaccine’s approval chances since it would ultimately be determined by the results of the other trials.

And Prof. Robin Shattock of London’s Imperial College, who is developing a separate COVID-19 vaccine, told the Times that the gap in doses could improve protection from the disease.

“The one month hold (for the US trial) likely reflects that the FDA (Food and Drug Administration) have not felt that they have been given enough information to allow the trial to restart,” he said.


India accelerates free trade agreements against backdrop of US tariffs

Updated 21 December 2025
Follow

India accelerates free trade agreements against backdrop of US tariffs

  • India signed a CEPA with Oman on Thursday and a CETA with the UK in July 
  • Delhi is also in advanced talks for trade pacts with the EU, New Zealand, Chile 

NEW DELHI: India has accelerated discussions to finalize free trade agreements with several nations, as New Delhi seeks to offset the impact of steep US import tariffs and widen export destinations amid uncertainties in global trade. 

India signed a Comprehensive Economic Partnership Agreement with Oman on Thursday, which allows India to export most of its goods without paying tariffs, covering 98 percent of the total value of India’s exports to the Gulf nation. 

The deal comes less than five months after a multibillion-dollar trade agreement with the UK, which cut tariffs on goods from cars to alcohol, and as Indian trade negotiators are in advanced talks with New Zealand, the EU and Chile for similar partnerships. 

They are part of India’s “ongoing efforts to expand its trade network and liberalize its trade,” said Anupam Manur, professor of economics at the Takshashila Institution. 

“The renewed efforts to sign bilateral FTAs are partly an after-effect of New Delhi realizing the importance of diversifying trade partners, especially after India’s biggest export market, the US, levied tariff rates of up to 50 percent on India.” 

Indian exporters have been hit hard by the hefty tariffs that went into effect in August. 

Months of negotiations with Washington have not clarified when a trade deal to bring down the tariffs would be signed, while the levies have weighed on sectors such as textiles, auto components, metals and labor-intensive manufacturing. 

The FTAs with other nations will “help partially in mitigating the effects of US tariffs,” Manur said. 

In particular, Oman can “act as a gateway to other Gulf countries and even parts of Eastern Europe, Central Asia, and Africa,” and the free trade deal will most likely benefit “labor-intensive sectors in India,” he added. 

The chances of concluding a deal with Washington “will prove to be difficult,” said Arun Kumar, a retired economics professor at the Jawaharlal Nehru University.

“With the US, the chances of coming to (an agreement) are a bit difficult, because they want to get our agriculture market open, which we cannot do. They want us to reduce trade with Russia. That’s also difficult for India to do,” he told Arab News.  

US President Donald Trump has threatened sanctions over India’s historic ties with Moscow and its imports of Russian oil, which Washington says help fund Moscow’s ongoing war with Ukraine.

“President Trump is constantly creating new problems, like with H-1B visa and so on now. So some difficulty or the other is expected. That’s why India is trying to build relationships with other nations,” Kumar said, referring to increased vetting and delays under the Trump administration for foreign workers, who include a large number of Indian nationals. 

“Substituting for the US market is going to be tough. So certainly, I think India should do what it can do in terms of promoting trade with other countries.” 

India has free trade agreements with more than 10 countries, including comprehensive economic partnership agreements with South Korea, Japan, and the UAE.

It is in talks with the EU to conclude an FTA, amid new negotiations launched this year for trade agreements, including with New Zealand and Chile.  

India’s approach to trade partnerships has been “totally transformed,” Commerce and Industry Minister Piyush Goyal said in a press briefing following the signing of the CEPA with Oman, which Indian officials aim to enter into force in three months. 

“Now we don’t do FTAs with other developing nations; our focus is on the developed world, with whom we don’t compete,” he said. “We complement and therefore open up huge opportunities for our industry, for our manufactured goods, for our services.”